Review ArticleReviews and Commentaries

Diabetic Nephropathy for the Primary Care Provider: New Understandings on Early Detection and Treatment

Andrew Kowalski, Armand Krikorian and Edgar V. Lerma
Ochsner Journal September 2014, 14 (3) 369-379;

REFERENCES

  1. ↵
    1. Radbill B,
    2. Murphy B,
    3. LeRoith D
    (12, 2008) Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc 83(12):1373–1381, pmid:19046557.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Wolf G,
    2. Ritz E
    (5, 2003) Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 14(5):1396–1405, pmid:12707409.
    OpenUrlFREE Full Text
  3. ↵
    1. Tripathi YB,
    2. Yadav D
    (1, 2013) Diabetic nephropathy: causes and managements. Recent Pat Endocr Metab Immune Drug Discov 7(1):57–64, pmid:23227864.
    OpenUrlPubMed
  4. ↵
    1. Yang CW,
    2. Park JT,
    3. Kim YS,
    4. et al.
    (10, 2011) Prevalence of diabetic nephropathy in primary care type 2 diabetic patients with hypertension: data from the Korean Epidemiology Study on Hypertension III (KEY III study). Nephrol Dial Transplant 26(10):3249–3255, pmid:21372264, Epub 2011 Mar 3.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Gross JL,
    2. de Azevedo MJ,
    3. Silveiro SP,
    4. Canani LH,
    5. Caramori ML,
    6. Zelmanovitz T
    (1, 2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28(1):164–176, pmid:15616252.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. de Boer IH,
    2. Rue TC,
    3. Hall YN,
    4. Heagerty PJ,
    5. Weiss NS,
    6. Himmelfarb J
    (6 22, 2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305(24):2532–2539, pmid:21693741.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. National Kidney Foundation
    (2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886, pmid:23067652.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Sharma K,
    2. Thompson SC,
    3. Goldfarb S
    (9, 2012) Diabetic kidney disease. NephSAP 11(5):S303–S372.
    OpenUrl
  9. ↵
    1. Sun YM,
    2. Su Y,
    3. Li J,
    4. Wang LF
    (4 19, 2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433(4):359–361, pmid:23541575, Epub 2013 Mar 26.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Molitch ME,
    2. DeFronzo RA,
    3. Franz MJ,
    4. et al.
    (1, 2004) American Diabetes Association. Nephropathy in diabetes. Diabetes Care 27(Suppl 1):S79–S83, pmid:14693934.
    OpenUrlCrossRefPubMed
  11. ↵
    (1, 2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intl 3(1):1–150.
    OpenUrlCrossRef
  12. ↵
    1. Van Buren PN,
    2. Toto R
    (1 1, 2013) Current update in the management of diabetic nephropathy. Curr Diabetes Rev 9(1):62–77, pmid:23167665.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Caramori ML,
    2. Fioretto P,
    3. Mauer M
    (4, 2003) Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52(4):1036–1040, pmid:12663477.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. MacIsaac RJ,
    2. Tsalamandris C,
    3. Panagiotopoulos S,
    4. Smith TJ,
    5. McNeil KJ,
    6. Jerums G
    (1, 2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27(1):195–200, pmid:14693989.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Friedman R,
    2. Gross JL
    (5, 1991) Evolution of glomerular filtration rate in proteinuric NIDDM patients. Diabetes Care 14(5):355–359, pmid:2060446.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Chudleigh RA,
    2. Dunseath G,
    3. Evans W,
    4. et al.
    (2, 2007) How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 30(2):300–305, pmid:17259498.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Poggio ED,
    2. Wang X,
    3. Greene T,
    4. Van Lente F,
    5. Hall PM
    (2, 2005) Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16(2):459–466, pmid:15615823, Epub 2004 Dec 22.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Knight EL,
    2. Verhave JC,
    3. Spiegelman D,
    4. et al.
    (4, 2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65(4):1416–1421, pmid:15086483.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Mussap M,
    2. Dalla Vestra M,
    3. Fioretto P,
    4. et al.
    (4, 2002) Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 61(4):1453–1461, pmid:11918752.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Stevens LA,
    2. Coresh J,
    3. Schmid CH,
    4. et al.
    (3, 2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51(3):395–406, pmid:18295055.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Zürbig P,
    2. Jerums G,
    3. Hovind P,
    4. et al.
    (12, 2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61(12):3304–3313, pmid:22872235, Epub 2012 Aug 7.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Schernthaner G,
    2. Schernthaner GH
    (Nov-Dec 2013) Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. J Nephrol 26(6):975–985, pmid:23807645, Epub 2013 Jun 14.
    OpenUrlPubMed
  23. ↵
    1. Coca SG,
    2. Ismail-Beigi F,
    3. Haq N,
    4. Krumholz HM,
    5. Parikh CR
    (5 28, 2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172(10):761–769, pmid:22636820, Erratum in: Arch Intern Med. 2012 Jul 23;172(14):1095.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. ADVANCE Collaborative Group,
    2. Patel A,
    3. MacMahon S,
    4. Chalmers J,
    5. et al.
    (6 12, 2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–7252, pmid:18539916, Epub 2008 Jun 6.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Ismail-Beigi F,
    2. Craven T,
    3. Banerji MA,
    4. et al.
    (8 7, 2010) ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376(9739):419–430, pmid:20594588, Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Ismail-Beigi F
    (4 5, 2012) Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 366(14):1319–1327, pmid:22475595.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. American Diabetes Association
    (1, 2012) Standards of medical care in diabetes–2012. Diabetes Care 35(Suppl 1):S11–S63, pmid:22187469.
    OpenUrlFREE Full Text
  28. ↵
    1. Zanchi A,
    2. Lehmann R,
    3. Philippe J
    (9, 2012) Antidiabetic drugs and kidney disease–recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly 13. .
  29. ↵
    1. Ferrannini E,
    2. Veltkamp SA,
    3. Smulders RA,
    4. Kadokura T
    (5, 2013) Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36(5):1260–1265, pmid:23359360, Epub 2013 Jan 28.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Cherney DZ,
    2. Perkins BA,
    3. Soleymanlou N,
    4. et al.
    (2 4, 2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597, pmid:24334175, Epub 2013 Dec 13.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Heaf JG,
    2. van Biesen W
    (7, 2011) Metformin and chronic renal impairment: A story of choices and ugly ducklings. Clin Diabetes 29(3):97–101.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Germino FW
    (12, 2011) Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clin Ther 33(12):1868–1882, pmid:22136979, Epub 2011 Dec 2.
    OpenUrlCrossRefPubMed
  33. ↵
    1. ACCORD Study Group,
    2. Cushman WC,
    3. Evans GW,
    4. Byington RP,
    5. et al.
    (4 29, 2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575–1585, pmid:20228401, Epub 2010 Mar 14.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. James PA,
    2. Oparil S,
    3. Carter BL,
    4. et al.
    (2014) evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5; 311(5):507–520, Erratum in: JAMA. 2014 May 7;311(17):1809.
    OpenUrl
  35. ↵
    1. Lewis EJ,
    2. Hunsicker LG,
    3. Bain RP,
    4. Rohde RD
    (11 11, 1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20):1456–1462, pmid:8413456, Erratum in: N Engl J Med. 1993 Jan 13;330(2):152.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Brenner BM,
    2. Cooper ME,
    3. de Zeeuw D,
    4. et al.
    (9 20, 2001) RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869, pmid:11565518.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Barnett AH,
    2. Bain SC,
    3. Bouter P,
    4. et al.
    (11 4, 2004) Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351(19):1952–1961, pmid:15516696, Epub 2004 Oct 31. Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Mann JF,
    2. Schmieder RE,
    3. McQueen M,
    4. et al.
    (8 16, 2008) ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553, pmid:18707986.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Fried LF,
    2. Emanuele N,
    3. Zhang JH,
    4. et al.
    (11 14, 2013) VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903, pmid:24206457, Epub 2013 Nov 9.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Makani H,
    2. Bangalore S,
    3. Desouza KA,
    4. Shah A,
    5. Messerli FH
    (1, 2013) Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 28. .
  41. ↵
    1. Persson F,
    2. Rossing P,
    3. Reinhard H,
    4. et al.
    (10, 2009) Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32(10):1873–1879, pmid:19587362, Epub 2009 Jul 8.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Parving HH,
    2. Brenner BM,
    3. McMurray JJ,
    4. et al.
    (5, 2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24(5):1663–1671, pmid:19145003, Epub 2009 Jan 14.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Schjoedt KJ,
    2. Rossing K,
    3. Juhl TR,
    4. et al.
    (8, 2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70(3):536–542, pmid:16775595, Epub 2006 Jun 14.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Zhou C,
    2. Lu F,
    3. Cao K,
    4. Xu D,
    5. Goltzman D,
    6. Miao D
    (7, 2008) Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74(2):170–179, pmid:18385669, Epub 2008 Apr 2.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Li YC
    (1, 2011) Podocytes as target of vitamin D. Curr Diabetes Rev 7(1):35–40, pmid:21067507.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Brown JM,
    2. Secinaro K,
    3. Williams JS,
    4. Vaidya A
    (Aug 23 2013) Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study. BMC Endocr Disord 13(1):33, pmid:23971740, [Epub ahead of print].
    OpenUrlPubMed
  47. ↵
    1. Pergola PE,
    2. Raskin P,
    3. Toto RD,
    4. et al.
    (7 28, 2011) BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365(4):327–336, pmid:21699484, Epub 2011 Jun 24.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. de Zeeuw D,
    2. Akizawa T,
    3. Audhya P,
    4. et al.
    (12 26, 2013) BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369(26):2492–2503, pmid:24206459, Epub 2013 Nov 9.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Pollock D
    (1, 2014) Learning from failure: New therapy for diabetic nephropathy and beyond. Kidney News 6(1), http://onlinedigeditions.com/article/Learning_From_Failure%3A_New_Therapy_For_Diabetic_Nephropathy_And_Beyond%3F/1605700/191174/article.html. Accessed January 27, 2014.
  50. ↵
    1. Nezu U,
    2. Kamiyama H,
    3. Kondo Y,
    4. Sakuma M,
    5. Morimoto T,
    6. Ueda S
    (May 28 2013) Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open 3(5). .
  51. ↵
    1. Go AS,
    2. Mozaffarian D,
    3. Roger VL,
    4. et al.
    (1 1, 2013) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127(1):e6–e245, pmid:23239837, Epub 2012 Dec 12. Erratum in: Circulation. 2013 Jun 11;127(23):e841.
    OpenUrlFREE Full Text
  52. ↵
    1. Hossain P,
    2. Kawar B,
    3. El Nahas M
    (1 18, 2007) Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 356(3):213–215, pmid:17229948, Erratum in: N Engl J Med. 2007 Mar 1;356(9):973.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Noborisaka Y
    (Winter 2013) Smoking and chronic kidney disease in healthy populations. Nephrourol Mon 5(1):655–667, pmid:23577327, Epub 2012 Dec 15.
    OpenUrlPubMed
  54. ↵
    1. Ansquer JC,
    2. Foucher C,
    3. Rattier S,
    4. Taskinen MR,
    5. Steiner G,
    6. Investigators DAIS
    (3, 2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45(3):485–493, pmid:15754270.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Abe M,
    2. Maruyama N,
    3. Okada K,
    4. Matsumoto S,
    5. Matsumoto K,
    6. Soma M
    (2011) Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 18(11):1018–1028, pmid:21921413, Epub 2011 Sep 15.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Tonelli M,
    2. Wanner C
    (2 4, 2014) Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 160(3):182, pmid:24323134.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords